Wells Fargo analyst Colin Langan lowered the firm’s price target on Cerence (CRNC) to $10 from $12 and keeps an Equal Weight rating on the shares. The firm notes that the company’s Q2 beat and management’s guided FY25 raises margin guidance. The free cash flow turnaround came just in time ahead of the June 2025 convert expiration. While Cerence continues its turnaround, Wells remains on the sidelines given market risk and valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNC: